Lv51
1226 积分 2020-08-09 加入
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
8天前
已完结
Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
10天前
已完结
The immunology of vitiligo
13天前
已完结
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
21天前
已完结
Hepatitis B
22天前
已关闭
Eli Lilly inks dual-payload ADCs deal
26天前
已关闭
Ivonescimab in advanced squamous non-small-cell lung cancer: can we raise the survival bar?
29天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
1个月前
已完结
An Update on Patent issues regarding Antibody Drug Conjugates
1个月前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
1个月前
已完结
皖公网安备34019202002308
